Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial
about
Towards tumor immunodiagnosticsTumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast CancerMarrow-Infiltrating Lymphocytes - Role in Biology and Cancer TherapyNeoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumabRelevance of tumor-infiltrating lymphocytes in breast cancerRestoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and PreventionThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyTranslating neoadjuvant therapy into survival benefits: one size does not fit all.Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategiesPrecision medicine in breast cancer: reality or utopia?Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomesThe Role of Neoadjuvant Trials in Drug Development for Solid Tumors.The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant populationAntibody-supervised deep learning for quantification of tumor-infiltrating immune cells in hematoxylin and eosin stained breast cancer samples.A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant SettingPrognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapiesTumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer.Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis.Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers.Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patientsReactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change afClinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.HER2-positive breast cancer is lost in translation: time for patient-centered research.Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.The molecular basis of breast cancer pathological phenotypes.Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation.Advancing Immunotherapy in Metastatic Breast Cancer.De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.
P2860
Q26738691-EB920505-A47E-4CB1-B576-76E23FC7DF52Q26745446-B385041C-EF93-4298-810E-A58E1D584968Q26749560-6E6AE238-CC4E-48B1-B434-6F2E95D751CFQ26764879-8C7B5600-BED0-473D-91D1-B2BBFCA4BF62Q26795598-412AEEAF-9BF9-4DBC-AA9E-DB90ECCD3727Q28067145-B2BE92CF-5E73-495F-AB46-2276FC55327AQ28076473-3CAE230E-A225-4859-BA07-D301BF239CFCQ30251738-D0AED7DC-D7EB-4E53-A64B-6B8324CCE99FQ30275647-D828C69C-D596-49ED-B711-067929207268Q33809114-4289E7B5-65BF-4D88-8BDB-BAABFEED9068Q33814856-19816ADF-B5F5-4731-9B32-0C08F479DBE3Q33886353-7A4B35F0-E87F-47A9-8C56-8480EFAAF772Q33915044-40C74F51-C37E-48C3-9437-63F5087106E0Q36149520-9E86AF81-0F33-46E3-95BF-93AB38D1D527Q36186223-90B7A2BC-B7C2-4AD6-A7D8-6F27047DF594Q36231343-629F1ADC-B300-42B2-8708-3E894863AF4AQ36545717-F9600294-2ECD-4E1E-9253-40CD18110EC3Q36673469-2949C144-FA65-4A12-A54B-4FA866333089Q37075648-65E35C3C-F140-4F3C-B915-29D7764AD776Q37160109-03FB05D9-1AEF-43E6-96FD-1A6181CB0C1BQ37190289-1169CB80-3709-47E7-B365-4DA79AAC7494Q37536862-9008E5D9-A24D-40C7-8C6F-432C66B10E7DQ37536901-F39AC1E7-D90A-41B1-8D62-B0B9286CDA25Q37544396-AEBDB222-D2D6-4FBF-A700-4F4BD3752003Q37593573-D22B73D3-1F71-4B91-BA00-16F4414DD73AQ38373249-35060D15-25FF-4946-B211-6A3135BE55D5Q38376822-8E4DA282-ED85-43EF-B0BE-E498EB501A24Q38387030-0E1AEA90-ECFA-4830-8E0C-6BDDC2CAFDEFQ38411841-68D92920-B955-44FD-BCCF-D027930C5552Q38639746-EC1A7929-6A96-4C40-9C07-739702FF79DFQ38648765-BDC70CC4-6DC4-4795-AD66-EF5F086EB32CQ38786102-AF719E77-5FBE-4663-805B-5F89565B48F9Q38823649-79745709-5FD2-4249-A047-8D4486492C5BQ39175548-17465393-85AF-4B7D-8E0F-7182A2B4149DQ39321597-3AD703A9-5FEC-468D-AACE-62229C558832Q39324161-E7E80BF8-70DB-4AAF-A342-07768A2C3841Q39421814-3EFE7EE5-71A7-4BBB-A460-C15E823185FFQ39638185-3D7D25BC-AFE5-4610-8DC2-36C075427520Q40284336-6F05F1D9-2AD7-4271-870C-D9C11C371B0BQ40521722-010AB026-A5B4-4FBA-94E0-F7E1ABA615CC
P2860
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Tumor-Infiltrating Lymphocytes ...... Analysis of the NeoALTTO Trial
@en
type
label
Tumor-Infiltrating Lymphocytes ...... Analysis of the NeoALTTO Trial
@en
prefLabel
Tumor-Infiltrating Lymphocytes ...... Analysis of the NeoALTTO Trial
@en
P2093
P2860
P50
P1433
P1476
Tumor-Infiltrating Lymphocytes ...... Analysis of the NeoALTTO Trial
@en
P2093
Catherine E Ellis
Christine Campbell
Christos Sotiriou
Claudia Aura
Holger Eidtmann
Ian Bradbury
Martine J Piccart-Gebhart
Peter Savas
Roberto Salgado
P2860
P304
P356
10.1001/JAMAONCOL.2015.0830
P577
2015-07-01T00:00:00Z